

# NIMOTOP<sup>®</sup>

nimodipine

**NOW AVAILABLE  
NEW NIMOTOP<sup>®</sup> I.V.**

- The first and only adjunctive therapy to improve the neurological outcome in SAH patients.
- Proven effective in significantly increasing the number of patients with good recovery and reducing the incidence of poor outcomes.

Improve the neurological outcome of your SAH patients with NIMOTOP.



**NIMOTOP<sup>®</sup>**  
nimodipine

**Improving the outcome**

For complete information see Product Monograph or call your local Miles Canada Sales Representative

#### References

1. Pickard, J.D. et al.: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysm nimodipine trial. *Brit Med J* March 11, 1989; 298, 636-642.

Pharmaceutical Division  
MILES CANADA INC.  
77 Belfield Road  
Etobicoke, Ontario M9W 1G6

© Miles Canada Inc., 1990.  
® Registered Trademark  
Miles Canada Inc. is the Registered  
User of the Trademark NIMOTOP<sup>®</sup>,  
the original brand of nimodipine.